Non-Opioid Pain Management Market Report 2026

Non-Opioid Pain Management Market Overview

• Non-Opioid Pain Management market size has reached to $44.93 billion in 2025 • Expected to grow to $68.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Prevalence Of Chronic Pain Conditions Driving Growth Of The Market Due To Aging Population And Increasing Musculoskeletal Disorders • Market Trend: Innovative Non-Opioid Oral Analgesics Enhance Safe And Effective Acute Pain Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Opioid Pain Management Market?

Non-opioid pain management refers to treating acute and chronic pain using therapies that exclude opioid-based medications. Its main purpose is to deliver safe, effective, and long-term pain relief and enhance patient mobility, recovery, and quality of life while reducing the risks of opioid dependency and adverse side effects. The main drug classes of non-opioid pain management include nonsteroidal anti-inflammatory drugs, antidepressants, local anesthetics, anticonvulsants, and other drug classes. Nonsteroidal anti-inflammatory drugs refer to medications that reduce pain and inflammation by inhibiting cyclooxygenase enzymes and are widely used for both acute and chronic pain conditions. These therapies are categorized by indication including chronic pain and acute pain and are distributed through hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. They find application in neuropathic pain, musculoskeletal pain, cancer pain, post-operative pain, and migraine, serving end users including hospitals, clinics, ambulatory surgical centers, rehabilitation centers, and home care settings.

What Is The Non-Opioid Pain Management Market Growth Forecast?

The non-opioid pain management market size is expected to see strong growth in the next few years. It will grow to $68.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing adoption of AI-based pain assessment tools, increasing investment in personalized medicine and genomics, expansion of digital health and remote patient monitoring, rising demand for non-invasive and drug-free therapies, integration of wearable and connected healthcare devices. Major trends in the forecast period include rising adoption of multimodal non-opioid therapies combining pharmacological and physical interventions, increasing use of digital therapeutics for chronic pain monitoring and management, growing preference for personalized pain treatment protocols based on patient profiling, expansion of minimally invasive and regenerative pain relief techniques, increasing integration of wearable devices for real-time pain tracking and rehabilitation support.

Global Non-Opioid Pain Management Market Segmentation

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs; Antidepressants; Local Anesthetics; Anticonvulsants; Other Drug Classes 2) By Indication: Chronic Pain; Acute Pain 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies 4) By Application: Neuropathic Pain; Musculoskeletal Pain; Cancer Pain; Post-Operative Pain; Migraine 5) By End User: Hospitals; Clinics; Ambulatory Surgical Centers; Rehabilitation Centers; Home Care Settings Subsegments: 1) By Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen; Naproxen; Diclofenac 2) By Antidepressants: Tricyclic Antidepressants; Serotonin-Norepinephrine Reuptake Inhibitors; Selective Serotonin Reuptake Inhibitors 3) By Local Anesthetics: Lidocaine; Bupivacaine; Ropivacaine 4) By Anticonvulsants: Gabapentin; Pregabalin; Carbamazepine 5) By Other Drug Classes: Muscle Relaxants; Capsaicin Based Therapies; Cannabinoid Based Therapies

What Is The Driver Of The Non-Opioid Pain Management Market?

The rising prevalence of chronic pain conditions is expected to propel the growth of the non-opioid pain management market going forward. Chronic pain conditions are disorders that cause persistent or recurring pain lasting longer than three months and can affect daily functioning and quality of life. Chronic pain conditions are increasing due to the rising aging population, as older individuals are more prone to developing long-term pain from age-related musculoskeletal and nerve disorders. Non-opioid pain management helps chronic pain conditions by reducing persistent pain and inflammation while improving mobility and daily functioning without the dependency risks associated with opioid medications. For instance, in February 2025, Arthritis Australia, an Australia-based non-profit organization, estimates that approximately 5.39 million Australians will be living with arthritis, representing a 31% increase since 2025. Therefore, the rising prevalence of chronic pain conditions is driving the growth of the non-opioid pain management industry.

Key Players In The Global Non-Opioid Pain Management Market

Major companies operating in the non-opioid pain management market are Johnson & Johnson; Pfizer Inc.; Bayer AG; Abbott Laboratories; Eli Lilly and Company; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd.; Haleon plc; Sun Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Perrigo Company plc; Aurobindo Pharma; Cipla Ltd.; Lupin Limited; Amneal Pharmaceuticals; Zydus Lifesciences; Pacira BioSciences Inc.; Alvogen; Heron Therapeutics; Hyloris Pharmaceuticals; Pierrel S.p.A.; Regenexbio.

Global Non-Opioid Pain Management Market Trends and Insights

Major companies operating in the non-opioid pain management market are focusing on developing innovative solutions, such as non-opioid oral analgesics, to provide effective pain relief with reduced risk of addiction and fewer side effects compared to opioid-based therapies. Non-opioid oral analgesics are orally administered pain-relief medications used to manage mild to moderate pain without opioid compounds, helping reduce the risk of dependence while effectively treating conditions such as headaches, arthritis, musculoskeletal disorders, and post-operative pain. For instance, in January 2025, Vertex Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic indicated for the treatment of moderate to severe acute pain in adults. The therapy works by selectively targeting NaV1.8 sodium channels in the peripheral nervous system, helping block pain signals before they reach the brain. This approval marked a significant advancement in non-opioid pain management by providing an effective alternative to opioid-based therapies.

What Are Latest Mergers And Acquisitions In The Non-Opioid Pain Management Market?

In May 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired SiteOne Therapeutics Inc. for $1 billion. With this acquisition, Eli Lilly and Company aims to strengthen its non-opioid pain management pipeline by advancing innovative therapies that provide effective pain relief with lower risks of addiction and side effects associated with opioids. SiteOne Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company that offers non-opioid pain management treatments.

Regional Outlook

North America was the largest region in the non-opioid pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Opioid Pain Management Market?

The non-opioid pain management market consists of sales of nerve stimulators, pain relief patches, and radiofrequency ablation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Opioid Pain Management Market Report 2026?

The non-opioid pain management market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain management industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.